Madaan Vishal, Chang Kiki D
Creighton University/University of Nebraska Medical Center, Omaha, NE 68131, USA.
Expert Opin Pharmacother. 2007 Aug;8(12):1801-19. doi: 10.1517/14656566.8.12.1801.
There has been a recent increase in recognition and diagnosis of pediatric bipolar disorder (PBD), along with an increase in prescriptions for psychotropic medications for treating children suffering from this chronic, potentially disabling disorder. Lithium remains the only FDA-approved mood stabilizer for use in children > 12 years of age and along with valproic acid and carbamazepine, forms the triad of traditional mood stabilizers used for initiation of treatment for PBD. There has been a recent surge in the use of atypical antipsychotics in PBD, which may be due to their relative ease of administration and lack of requirement for serum level monitoring. A combination of traditional mood stabilizers along with atypical antipsychotics is commonly used in clinical practice, despite a lack of compelling empirical data. Although there is an urgent need for controlled studies on the available treatment options and strategies in PBD, recent expert consensus guidelines and emerging controlled pharmacotherapy data on PBD will lay the platform for future scientific research in the area.
近年来，儿童双相情感障碍（PBD）的识别和诊断有所增加，用于治疗患有这种慢性、可能致残疾病的儿童的精神药物处方也有所增加。锂仍然是美国食品药品监督管理局（FDA）批准的唯一可用于12岁以上儿童的情绪稳定剂，与丙戊酸和卡马西平一起，构成了用于启动PBD治疗的传统情绪稳定剂三联组。最近，非典型抗精神病药物在PBD中的使用激增，这可能是由于其给药相对容易且无需监测血清水平。尽管缺乏令人信服的经验数据，但传统情绪稳定剂与非典型抗精神病药物联合使用在临床实践中很常见。虽然迫切需要对PBD现有的治疗选择和策略进行对照研究，但最近关于PBD的专家共识指南和新出现的对照药物治疗数据将为该领域未来的科学研究奠定基础。
